📊 EVGN Key Takeaways
Is Evogene Ltd. (EVGN) a Good Investment?
Evogene Ltd. presents severe analytical challenges due to complete absence of fundamental financial data, preventing any meaningful assessment of profitability, financial health, or operational performance. The company appears to be either pre-revenue, in a development stage, or experiencing significant financial reporting issues that preclude fundamental analysis.
Evogene showed improving top-line momentum in 2024, with revenue rising to about $8.5 million from $5.6 million and operating loss narrowing to about $22.2 million from $26.5 million. However, the business remains deeply unprofitable, burned about $19.7 million in operating cash flow, and disclosed conditions that had raised substantial doubt about its ability to continue as a going concern. The improvement in net loss was also helped by warrant-related non-cash financing income, which lowers the quality of the earnings improvement.
Why Buy Evogene Ltd. Stock? EVGN Key Strengths
- Listed on Nasdaq indicating some level of regulatory compliance and market access
- Operates in agricultural chemicals sector which has structural demand drivers
- Capacity to raise capital through public markets
- Revenue grew materially in 2024, driven by collaboration income and higher seed sales
- R&D spending declined meaningfully, helping reduce operating losses
- Year-end cash and equivalents of about $15.3 million provided some near-term liquidity support
EVGN Stock Risks: Evogene Ltd. Investment Risks
- Complete lack of revenue data suggests no viable business operations or severe commercial failure
- Absence of balance sheet metrics indicates potential financial distress or ongoing losses unsustainable for operations
- Zero insider trading activity in last 90 days suggests management confidence concerns or operational stagnation
- Inability to conduct fundamental analysis due to missing financial statements creates unquantifiable investment risk
- Agricultural chemicals sector requires significant capital and R&D investment which company cannot demonstrate funding for
- Core profitability remains very weak, with operating losses still far larger than revenue
- Operating cash burn is high relative to cash on hand, increasing financing risk
- Revenue appears lumpy and dependent on collaboration milestones, delivery timing, and subsidiary execution
Key Metrics to Watch
- Revenue and gross profit realization from any commercial products or partnerships
- Cash burn rate and runway given apparent lack of operating revenue
- Balance sheet strength and access to capital for ongoing operations and R&D
- Quarterly operating cash burn versus cash balance
- Revenue conversion from collaborations and seed deliveries into sustained gross profit and lower operating loss
Evogene Ltd. (EVGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EVGN Profit Margin, ROE & Profitability Analysis
EVGN vs Materials Sector: How Evogene Ltd. Compares
How Evogene Ltd. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Evogene Ltd. Stock Overvalued? EVGN Valuation Analysis 2026
Based on fundamental analysis, Evogene Ltd. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Evogene Ltd. Balance Sheet: EVGN Debt, Cash & Liquidity
EVGN Revenue Growth, EPS Growth & YoY Performance
EVGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Evogene Ltd. (CIK: 0001574565)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EVGN
What is the AI rating for EVGN?
Evogene Ltd. (EVGN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EVGN's key strengths?
Claude: Listed on Nasdaq indicating some level of regulatory compliance and market access. Operates in agricultural chemicals sector which has structural demand drivers. ChatGPT: Revenue grew materially in 2024, driven by collaboration income and higher seed sales. R&D spending declined meaningfully, helping reduce operating losses.
What are the risks of investing in EVGN?
Claude: Complete lack of revenue data suggests no viable business operations or severe commercial failure. Absence of balance sheet metrics indicates potential financial distress or ongoing losses unsustainable for operations. ChatGPT: Core profitability remains very weak, with operating losses still far larger than revenue. Operating cash burn is high relative to cash on hand, increasing financing risk.
What is EVGN's revenue and growth?
Evogene Ltd. reported revenue of N/A.
Does EVGN pay dividends?
Evogene Ltd. does not currently pay dividends.
Where can I find EVGN SEC filings?
Official SEC filings for Evogene Ltd. (CIK: 0001574565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EVGN's EPS?
Evogene Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EVGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Evogene Ltd. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EVGN stock overvalued or undervalued?
Valuation metrics for EVGN: ROE of N/A (sector avg: 14%), net margin of N/A (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy EVGN stock in 2026?
Our dual AI analysis gives Evogene Ltd. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EVGN's free cash flow?
Evogene Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does EVGN compare to other Materials stocks?
Vs Materials sector averages: Net margin N/A (avg: 10%), ROE N/A (avg: 14%), current ratio N/A (avg: 1.6).